Article
Oncology
Xing Yi Woo, Anuj Srivastava, Philip C. Mack, Joel H. Graber, Brian J. Sanderson, Michael W. Lloyd, Mandy Chen, Sergii Domanskyi, Regina Gandour-Edwards, Rebekah A. Tsai, James Keck, Mingshan Cheng, Margaret Bundy, Emily L. Jocoy, Jonathan W. Riess, William Holland, Stephen C. Grubb, James G. Peterson, Grace A. Stafford, Carolyn Paisie, Steven B. Neuhauser, R. Krishna Murthy Karuturi, Joshy George, Allen K. Simons, Margaret Chavaree, Clifford G. Tepper, Neal Goodwin, Susan D. Airhart, Primo N. Lara, Thomas H. Openshaw, Edison T. Liu, David R. Gandara, Carol J. Bult
Summary: Patient-derived xenograft models are important preclinical platforms for testing cancer therapeutics. This study describes a repository of genetically and clinically annotated lung cancer PDX models, which have been extensively characterized for histopathologic features, mutational profiles, gene expression, and copy-number aberrations. The genomic profiles of the PDX models are consistent with patient tumors, and these models serve as valuable platforms for translational cancer research.
Article
Oncology
Xuanming Chen, Cheng Shen, Zhe Wei, Rui Zhang, Yongsheng Wang, Lili Jiang, Ke Chen, Shuang Qiu, Yuanli Zhang, Ting Zhang, Bin Chen, Yanjun Xu, Qiyi Feng, Jinxing Huang, Zhihui Zhong, Hongxia Li, Guowei Che, Kai Xiao
Summary: A large collection of serially transplantable PDX models for NSCLC were successfully developed, faithfully reproducing the molecular, histopathological, and therapeutic characteristics, as well as the corresponding tumor heterogeneities of primary tumors. PDX models responded differentially to the standard of care treatment, including chemo-, targeted and immuno-therapeutics, similar to clinical patients.
CANCER BIOLOGY & MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Bor-Shiuan Shyr, Chien-Sheng Huang, Hui-Shan Chen, Po-Kuei Hsu, Chao-Hua Chiu, Han-Shui Hsu, Chun-Ming Tsai, Yuh-Min Chen
Summary: This study aimed to investigate the impact of primary lung resection and systemic treatment on disease progression and survival in patients with oligometastatic NSCLC. The results showed no significant differences in perioperative complications, hospital length of stay, disease progression, overall death, median PFS, and OS between patients who received primary lung resection and systemic treatment. It was also found that patients with single-organ metastasis had significantly longer PFS and OS than those with oligometastases. Nonsolitary metastasis was identified as the only independent predictor of PFS.
ANNALS OF THORACIC SURGERY
(2022)
Article
Oncology
Pan Juncheng, Adrien Joseph, Antoine Lafarge, Isabelle Martins, Florine Obrist, Jonathan Pol, Ester Saavedra, Sijing Li, Allan Sauvat, Giulia Cerrato, Sarah Levesque, Marion Leduc, Oliver Kepp, Sylvere Durand, Fanny Aprahamian, Nitharsshini Nirmalathansan, Judith Michels, Guido Kroemer, Maria Castedo
Summary: This study found that high activity of PARP1 in non-small cell lung cancer cells affects the tumor microenvironment, leading to compromised immunosurveillance and reduced infiltration of cytotoxic T lymphocytes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Xuehan Chen, Yanzhuo Liu, Yang Wang, Chenlong Wang, Xuewei Chen, Yu Xiong, Lilong Liu, Xi Yuan, Honglin Tang, Chong Shu, Jing Zhang, Austin M. Guo, Honglei Chen, Jing Yang
Summary: Fatty acid synthesis and CYP4 co-hydroxylases play a role in tumor cell immune escape, and CYP4F2 specifically controls immune evasion in non-small cell lung cancer by regulating immune checkpoint expression and proangiogenic factor production.
Article
Cell Biology
Zi-Ning Lei, Qiu-Xu Teng, Pranav Gupta, Wei Zhang, Silpa Narayanan, Dong-Hua Yang, John N. D. Wurpel, Ying-Fang Fan, Zhe-Sheng Chen
Summary: The study demonstrates that CBZ can inhibit the ABCG2 transporter and resensitize drug-resistant cancer cells to specific drugs, showing promising reversal effects in an in vivo xenograft model.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Multidisciplinary Sciences
Zihan Zhou, Wenjie Guo, Dingqi Liu, Jose Ramon Nsue Micha, Yue Song, Shuhua Han
Summary: In this retrospective study, clinical signatures and radiomics variables were collected from 94 patients with advanced non-small cell lung cancer. Using principal component analysis and support vector machine, a predictive model was developed to identify patients who will achieve durable clinical benefit with chemo-immunotherapy.
SCIENTIFIC REPORTS
(2023)
Review
Immunology
Miguel Garcia-Pardo, Teresa Gorria, Ines Malenica, Stephanie Corgnac, Cristina Teixido, Laura Mezquita
Summary: Immunotherapy has revolutionized the oncology field and become a new standard of care for NSCLC. However, not all patients benefit from immunotherapy, and there is a need for further strategies to improve outcomes. Therapeutic cancer vaccines have the potential to boost antitumor immunity and work synergistically with immune checkpoint inhibitors. However, current vaccine immunization strategies for lung cancer have been unsuccessful. The success of COVID-19 vaccines raises hope that a similar strategy can be successful in cancer treatment.
Article
Medicine, General & Internal
Jingsheng Cai, Fan Yang, Xun Wang
Summary: This study aims to investigate occult non-small cell lung cancer (NSCLC), an underappreciated tumor, and found that it is an aggressive tumor with poor prognosis. Surgery is the preferred treatment. More attention should be paid to this overlooked disease due to no evidence of tumor imaging.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Shawn J. Rice, Chandra P. Belani
Summary: Blood-based biomarkers, including systemic inflammation indicators and circulating factors, are associated with poor prognosis in lung cancer patients. Elevated levels of inflammation markers were found in non-small cell lung cancer (NSCLC) patients compared to small cell lung cancer (SCLC) and disease-free (DF) patients. Specific markers were identified as predictors of progression and overall survival in NSCLC patients, highlighting the potential for personalized treatment strategies.
Article
Multidisciplinary Sciences
Qing Li, Zhen Lin, Ye Hong, Yang Fu, Yueyun Chen, Ting Liu, Yue Zheng, Jiangfang Tian, Chunhua Liu, Wei Pu, Zhenyu Ding, Chun Wang
Summary: Patients with advanced non-small cell lung cancer are susceptible to brain metastases, including brain parenchymal metastases and leptomeningeal metastases. Patients with leptomeningeal metastases have a higher proportion of EGFR exon 21 point mutations and shorter survival compared to patients without brain metastases or with brain parenchymal metastases. Two prediction models were developed to predict the development of brain parenchymal metastases and leptomeningeal metastases in advanced non-small cell lung cancer patients.
SCIENTIFIC REPORTS
(2022)
Review
Immunology
Ding-Yu Rao, De-Fa Huang, Mao-Yan Si, Hua Lu, Zhi-Xian Tang, Zu-Xiong Zhang
Summary: As an important mediator of information transfer between cells, exosomes play a unique role in regulating tumor growth, supporting vascular proliferation, tumor invasion, and metastasis. Exosomes can be used as a potential tool for non-invasive liquid biopsy due to their presence in various body fluids. This study reviews the role of exosomes in liquid biopsy, tumor microenvironment formation, and epithelial-mesenchymal transition in non-small cell lung cancer (NSCLC). It also discusses the occurrence of EGFR+ exosomes and the role of exosomes and their contents in non-invasive detection and potential therapeutic targets in EGFR-mutated lung cancer.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Yingsheng Wen, Guangran Guo, Longjun Yang, Lianjuan Chen, Dechang Zhao, Xiaotian He, Rusi Zhang, Zirui Huang, Gongming Wang, Lanjun Zhang
Summary: This study identified a potentially effective model for estimating overall survival in lung cancer patients by analyzing the tumor microenvironment (TME) components. A gene panel consisting of seven TME-related genes was proposed as a candidate signature set. The study also revealed that patients at high-risk had less immune cells infiltration and more fibroblasts in their tumor tissues, leading to a worse immunotherapy response.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Ciara Murphy, Gloria Gornes Pons, Anna Keogh, Lisa Ryan, Lorraine Mccarra, Chris Maria Jose, Shagun Kesar, Siobhan Nicholson, Gerard J. Fitzmaurice, Ronan Ryan, Vincent Young, Sinead Cuffe, Stephen P. Finn, Steven G. Gray
Summary: This study investigated the expression and potential clinical utility of JADE2 in non-small cell lung cancer (NSCLC). The results showed that JADE2 expression is significantly altered in NSCLC and high expression of JADE2 is associated with better overall survival. The study also identified associations between JADE2 expression and tumor mutational burden and immune cell infiltration, as well as potential new drugs targeting JADE2. Overall, JADE2 may have potential diagnostic, prognostic, and therapeutic implications in NSCLC.
Article
Medicine, General & Internal
Yi-Han Zuo, Wei-Na Gao, Ya-Jia Xie, Sheng-Yong Yang, Jin-Tai Zhou, Hai-Hai Liang, Xing-Xing Fan
Summary: PKC delta is identified as a critical factor in the non-inflamed tumor microenvironment (TME) of EGFR-mutated lung cancer. Inhibition of PKC delta enhances the infiltration of immune cells into tumors and increases the sensitivity of tumors to immune checkpoint blockade therapy.
Article
Oncology
Margarita Majem, Jonathan W. Goldman, Thomas John, Christian Grohe, Konstantin Laktionov, Sang-We Kim, Terufumi Kato, Huu Vinh Vu, Shun Lu, Shanqing Li, Kye Young Lee, Charuwan Akewanlop, Chong-Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Domine, Frances A. Shepherd, Shinji Atagi, Lingmin Zeng, Dakshayini Kulkarni, Nenad Medic, Masahiro Tsuboi, Roy S. Herbst, Yi-Long Wu
Summary: This study demonstrated that adjuvant osimertinib treatment maintained health-related quality of life in patients with completely resected EGFR-mutated non-small cell lung cancer, with no clinically meaningful differences compared to placebo.
CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Rachel Woodford, Deborah Zhou, Sarah J. Lord, Ian Marschner, Wendy A. Cooper, Craig R. Lewis, Thomas John, James Chih-Hsin Yang, Chee Khoon Lee
Summary: High PD-L1 expression in non-small-cell lung cancer (mNSCLC) is associated with longer overall survival and improved response rates to chemotherapy. However, different assay methods may impact the accuracy of these results.
Editorial Material
Oncology
Ming-Sound Tsao, Andrew G. Nicholson, Joseph J. Maleszewski, Alexander Marx, William D. Travis
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Microbiology
Jennifer Habel, Andrea Nguyen, Louise Rowntree, Christopher Szeto, Nicole Mifsud, E. Bridie Clemens, Liyen Loh, Weisan Chen, Steve Rockman, Jane W. Nelson, Jane Davies, Adrian Miller, Steven Y. C. T. Tong, Jamie Rossjohn, Stephanie M. Gras, Anthony Purcell, Luca M. Hensen, Katherine Kedzierska, Patricia M. Illing
Summary: HLA-A*11:01 is highly prevalent in East Asian and Oceanian populations and is associated with high risk of severe influenza disease. Using immunopeptidomics, researchers identified novel CD8(+) T cell targets for influenza A and influenza B viruses in HLA-A*11:01-expressing individuals. These findings have implications for the design of broadly cross-reactive influenza vaccines.
Review
Oncology
Jose Luis Leal, Thomas John
Summary: The treatment paradigm of non-small-cell lung cancer has changed significantly in recent years, with immune-checkpoint inhibitors becoming the standard of care. However, most patients still experience disease progression. This review discusses treatment alternatives after progression and mechanisms of resistance.
CLINICAL LUNG CANCER
(2022)
Article
Biochemistry & Molecular Biology
Cedric Zeltz, Maryam Khalil, Roya Navab, Ming-Sound Tsao
Summary: Collagen type XI restrains collagen remodeling and cell migration mediated by cancer-associated fibroblasts (CAF), thereby limiting the invasion of lung cancer cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
John F. Markham, Andrew P. Fellowes, Thomas Green, Jose Luis Leal, Roxane Legaie, Darren Cullerne, Tessa Morris, Tom John, Ben Solomon, Stephen B. Fox
Summary: This study investigates the use of targeted RNA sequencing to measure tumor mutational burden (TMB) and expression of immune-cell-restricted genes from FFPE specimens, and their predictive value for response to immune checkpoint blockade treatment in NSCLC patients. The results show that TMB calculated from targeted RNA sequencing correlates with TMB derived from DNA sequencing, and it can predict response to immune blockade treatment. However, the expression of immune-cell-restricted genes is not correlated with patient outcome.
BRITISH JOURNAL OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Xia Yang, Hailiang Sun, Zhening Zhang, Weixin Ou, Fengxiang Xu, Ling Luo, Yahong Liu, Weisan Chen, Jianxin Chen
Summary: Influenza A virus (IAV) infections pose a serious threat to public health and there is an urgent need for novel anti-IAV medications. This study reveals that ginsenoside rk1 (G-rk1) and G-rg5, derived from panax ginseng, exhibit significant antiviral effects against different IAV subtypes both in vitro and in vivo. G-rk1 specifically blocks IAV binding to sialic acid and interacts with HA1, making it a potential approach for preventing and treating IAV infections.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh S. Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A. Shepherd, Krishna C. Bulusu, Gianluca Laus, Barbara Collins, J. Carl Barrett, Ryan J. Hartmaier, Vassiliki Papadimitrakopoulou
Summary: The third-generation EGFR tyrosine kinase inhibitor osimertinib improves progression-free survival compared to platinum-doublet chemotherapy in patients with advanced NSCLC carrying EGFR T790M mutation. In this study, the authors used next-generation sequencing to evaluate the potential mechanisms of acquired resistance to osimertinib in patients from the AURA3 trial. Some patients had undetectable plasma EGFR T790M at disease progression and/or treatment discontinuation.
NATURE COMMUNICATIONS
(2023)
Article
Respiratory System
Lara Edbrooke, Catherine L. Granger, Jill J. Francis, Tom John, Nasreen Kaadan, Emma Halloran, Bronwen Connolly, Linda Denehy
Summary: This study aims to develop a core set of clinically relevant lung cancer rehabilitation outcomes for use in clinical practice, in order to improve function, health-related quality of life, and manage the high symptom burden associated with lung cancer. The research utilizes an international Delphi consensus study, involving various stakeholders, to determine the priority outcomes for a core outcome set (COS) for lung cancer rehabilitation.
BMJ OPEN RESPIRATORY RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Xia Yang, Feixiang Long, Weixin Jia, Mingxin Zhang, Guanming Su, Ming Liao, Zhenling Zeng, Weisan Chen, Jianxin Chen
Summary: We demonstrated that artemisinin and its derivative artesunate (AS) have broad antiviral activity against H5N1, H1N1, H3N2, and oseltamivir-resistant influenza A virus in vitro. AS treatment significantly protected mice from lethal challenges with H1N1 and H5N1 IAV, and the combination of AS and peramivir showed improved survival outcomes compared to monotherapy. Mechanistically, AS inhibited PDE4, induced cAMP accumulation, reduced ERK phosphorylation, and blocked IAV vRNP export, thus suppressing IAV replication.
ANTIVIRAL RESEARCH
(2023)
Editorial Material
Oncology
Hui Jing Hoe, Adithya Balasubramanian, Thomas John
JOURNAL OF THORACIC ONCOLOGY
(2023)
Review
Oncology
Joshua C. Rosen, Adrian Sacher, Ming-Sound Tsao
Summary: KRAS(G12C) inhibitors have shown promising results in clinical trials with overall response rates ranging between 32% and 46%, and have been granted FDA approvals as second-line or later monotherapies. However, rapid tumor resistance complicates their use as a monotherapy.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Oncology
Shelley Kuang, Andrea S. Fung, Kirstin A. Perdrizet, Kaitlin Chen, Janice J. N. Li, Lisa W. Le, Michael Cabanero, Ola Abu Al Karsaneh, Ming S. Tsao, Josh Morganstein, Laura Ranich, Adam C. Smith, Cuihong Wei, Carol Cheung, Frances A. Shepherd, Geoffrey Liu, Penelope Bradbury, Prodipto Pal, Joerg Schwock, Adrian G. Sacher, Jennifer H. Law, Tracy L. Stockley, Natasha B. Leighl
Summary: In NSCLC patients, reflex testing using NGS panels can identify actionable genetic variants in the majority of cases with minimal increase in testing cost. Implementation of NGS panels is essential for the treatment of NSCLC patients as treatment paradigms continue to evolve.
Meeting Abstract
Medicine, Research & Experimental
Ellen Yang, Najd Alshamlan, Jessica Weiss, Michael Cabanero, Ming Tsao
LABORATORY INVESTIGATION
(2022)